New York, March 16, 2016 -- Moody's Investors Service commented that Quest Diagnostics Incorporated's announcement that the company would tender for up to $200 million of its outstanding bonds is modestly credit positive because it will reduce interest cost. However, there is no impact on the company's Baa2 senior unsecured rating or stable outlook.
Vollständigen Artikel bei Moodys lesen
Nachrichten
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.